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Abstract Little is known about the excess mortality caused by multidrug-resistant (MDR)
bacterial infection in low- and middle-income countries (LMICs). We retrospectively obtained
microbiology laboratory and hospital databases of nine public hospitals in northeast Thailand from
2004 to 2010, and linked these with the national death registry to obtain the 30-day mortality
outcome. The 30-day mortality in those with MDR community-acquired bacteraemia, healthcare-
associated bacteraemia, and hospital-acquired bacteraemia were 35% (549/1555), 49% (247/500),
and 53% (640/1198), respectively. We estimate that 19,122 of 45,209 (43%) deaths in patients with
hospital-acquired infection due to MDR bacteria in Thailand in 2010 represented excess mortality
caused by MDR. We demonstrate that national statistics on the epidemiology and burden of MDR
in LMICs could be improved by integrating information from readily available databases. The
prevalence and mortality attributable to MDR in Thailand are high. This is likely to reflect the
situation in other LMICs.
DOI: 10.7554/eLife.18082.001
Introduction
The emergence of antimicrobial resistance (AMR) is of major medical concern, particularly in low-
and middle-income countries (LMICs) (World Health Organization, 2014; Laxminarayan et al.,
2013). In LMICs, antibiotic use is increasing with rising incomes, affordable antimicrobials and the
lack of stewardship in hospital and poor control of over-the-counter sales. This is driving the emer-
gence and spread of multidrug-resistant (MDR) pathogens in community and hospital settings. Hos-
pital data from LMICs suggest that the cumulative incidence of community-acquired Extended-
Spectrum Beta-Lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae infections
are increasing over time (Kanoksil et al., 2013; Ansari et al., 2015). A recent report from the Inter-
national Nosocomial Infection Control Consortium (INICC) also showed that the prevalence of AMR
organisms causing hospital-acquired infections (HAI) in ICUs in LMICs is much higher than those in
the United States (US) (Rosenthal et al., 2014).
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Attributable mortality, generally defined as the difference in mortality between those with and
without the condition of interest, is an important parameter used to estimate the burden of AMR. In
the US, it is estimated that mortality from infection attributable to AMR is 6.5%, (Roberts et al.,
2009) leading to an estimate of 23,000 deaths attributable to AMR each year (Center for Disease
Controls and Prevention and U.S. Department of Health and Human Services, 2013). In the Euro-
pean Union, it is estimated that the number of deaths attributable to selected antibiotic-resistant
bacteria is about 25,000 each year (European Centre for Disease Prevention and Control and
European Medicines Agency, 2009). There is limited information on mortality attributable to AMR
in LMICs. The mortality attributable to ventilator-associated pneumonia in ICUs in Colombia, Peru,
and Argentina is estimated to be 17%, 25%, and 35%, respectively, and is associated with a high
percentage of AMR organisms (Moreno et al., 2006; Cuellar et al., 2008; Rosenthal et al., 2003).
The mortality attributable to ESBL and methicillin-resistance Staphylococcus aureus (MRSA) is esti-
mated to be 27% and 34% in neonatal sepsis in Tanzania, respectively, (Kayange et al., 2010) which
has been used to postulate an estimate that 58,319 deaths could be attributable to ESBL and MRSA
in India alone (Laxminarayan et al., 2013). In an effort to harmonize the surveillance systems of
AMR, a joint initiative between the European Centre for Disease Prevention and Control (ECDC) and
the Centres for Disease Prevention and Control (CDC) have developed standard definitions of multi-
drug-resistance (MDR) (Magiorakos et al., 2012).
We recently combined large data sets from multiple sources including microbiology databases,
hospital admission databases, and the national death registry from a sample of ten public hospitals
in northeast Thailand from 2004 to 2010 (Kanoksil et al., 2013; Hongsuwan et al., 2014). We
defined community-acquired bacteraemia (CAB) as the isolation of a pathogenic bacterium from
blood taken in the first 2 days of admission and without a hospital stay in the 30 days prior to admis-
sion, healthcare-associated bacteraemia (HCAB) as the isolation of a pathogenic bacterium from
blood taken in the first 2 days of admission and with a hospital stay within 30 days prior to the
admission, and hospital-acquired bacteraemia (HAB) as the isolation of a pathogenic bacterium from
blood taken after the first 2 days of admission (Kanoksil et al., 2013; Hongsuwan et al., 2014). We
reported an increase in the incidence of CAB, HCAB and HAB over the study period, and that
eLife digest Antimicrobial resistance is a global problem. Each year, an estimated 23,000
deaths in the United States and 25,000 deaths in the European Union are extra deaths caused by
bacteria resistant to antibiotics. People in low- and middle-income countries are also using more
antibiotics, in part because of rising incomes, lower costs of antibiotics, and a lack of control of
antimicrobial usage in the hospitals and over-the-counter sales of the drugs. These factors are
thought to be driving the development and spread of bacteria that are resistant to multiple
antibiotics in countries such as China, India, Indonesia and Thailand. However, a lack of information
makes it difficult to estimate the size of the problem and, then, to track how antimicrobial resistance
and multi-drug resistance is changing over time in these and other low- and middle-income
countries.
Now, by integrating routinely collected data from a range of databases, Lim, Takahashi et al.
estimate that around an extra 19,000 deaths are caused by multi-drug resistant bacteria in Thailand
each year. Thailand has a population of about 70 million, and so, per capita, this estimate is about 3
to 5 times larger than those for the United States and European Union (which have a populations of
about 300 million and 500 million, respectively). Lim, Takahashi et al. also show that more of the
bacteria collected from patients are resistant to multiple antimicrobial drugs and that the burden of
antimicrobial resistance in Thailand is worsening over time.
These findings suggest that more studies with a systematic approach need to be done in other
low- and middle-income countries, especially in countries where microbiological laboratories are
readily available and routinely used. Further work is also needed to identify where resources and
attentions are most needed to effectively fight against antimicrobial resistance in low- and middle-
income countries.
DOI: 10.7554/eLife.18082.002
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bacteraemia was associated with high case fatality rates (37.5%, 41.8% and 45.5%, respectively)
(Kanoksil et al., 2013; Hongsuwan et al., 2014). Here, we apply ECDC/CDC standard definitions of
MDR to this large data set to evaluate the prevalence, trends, and mortality attributable to MDR
bacteria isolated from the blood. We then estimate the number of deaths attributable to MDR in
Thailand nationwide.
Results
We contacted all 20 provincial hospitals in Northeast Thailand to participate in the study. All provin-
cial hospitals were equipped with all basic medical specialties and intensive care units (ICUs). Agree-
ment was obtained from 15 (75%) hospitals, of which ten had hospital databases and
microbiological laboratory databases as electronic files in a readily accessible format
(Kanoksil et al., 2013; Hongsuwan et al., 2014). Of these ten hospitals, nine had databases of anti-
microbial susceptibility testing results as electronic files for the study (Figure 1). The median bed
number for the nine hospitals included in the analysis was 450 beds (range 300 to 1000 beds). Of
these, three had data available for the period 2004–2010, two between 2007 and 2010, three
between 2008 and 2010 and one between 2009 and 2010. Overall, 1,803,506 admission records
from 1,255,571 patients were evaluated. A total of 20,803 (1.2%) admission records had at least one
blood culture positive for pathogenic organisms during admission. Of 10,022 patients with first epi-
sodes of bacteraemia caused by S. aureus, Enterococcus spp, E. coli, K. pneumoniae, P. aeruginosa
and Acinetobacter spp., 226 patients (2%) were excluded because the causative organisms were
tested for susceptibility to fewer than three antimicrobial categories. Therefore, a total of 9796 first
episodes of bacteraemia caused by S. aureus (n = 1881), Enterococcus spp (n = 342), E. coli
(n = 4279), K. pneumoniae (n = 1661), P aeruginosa (n = 568), and Acinetobacter spp. (n = 1065)
were evaluated in the analysis. The proportion of bacteria being MDR was highest in HAB and lowest
in CAB for all organisms (all p<0.001 except for Enterococcus spp., Table 1).
Staphylococcus aureus
Of CAB, HCAB and HAB caused by S. aureus, 8%, 28%, and 50% were caused by MDR S. aureus,
respectively (p<0.001). Almost all MDR S. aureus were MRSA (92% [357/389], Table 2). We did not
observe a trend in the proportion of S. aureus bacteraemia being caused by MRSA (Figure 2). Van-
comycin non-susceptible S. aureus was found in <1% of tested isolates (6/1380).
Enterococcus species
MDR Enterococcus spp. were not found in CAB (0/176) and HCAB (0/49), while 3% (4/117) of
Enterococcus spp. causing HAB were MDR. Of CAB caused by Enterococcus spp., 15% (20/134) and
23% (35/153) was non-susceptible to ampicillin and gentamicin, respectively (Table 3), while 42%
(34/81) and 62% (63/101) of HAB caused by Enterococcus spp. were non-susceptible to those
agents, respectively (both p<0.001). Vancomycin non-susceptible Enterococcus spp. was found in
4% of tested isolates (15/338).
Escherichia coli
Of CAB, HCAB and HAB caused by E. coli, 35%, 58% and 63% were caused by MDR E. coli, respec-
tively (p<0.001). Of E. coli causing CAB, 79% (2246/2843), 16% (501/3076), 24% (728/3000), 58%
(1738/3007), and 17% (559/3346) were non-susceptible to commonly-used antimicrobials for com-
munity-acquired infections such as ampicillin, cefotaxime, ciprofloxacin, trimethoprim-sulphamethox-
azole, and gentamicin, respectively (Table 4). From 2004 to 2010, the proportions of community-
acquired E. coli bacteraemia being caused by E. coli non-susceptible to extended-spectrum cephalo-
sporins rose from 5% (9/169) to 23% (186/815) (p=0.04) (Figure 3). The proportions of healthcare-
associated and hospital-acquired E. coli bacteraemia being caused by E. coli non-susceptible to
extended-spectrum cephalosporins were high (44% [204/465] and 52% [190/368], respectively), but
a significant trend over time was not observed (p=0.18 and p=0.63, respectively). Carbapenem non-
susceptible E. coli was found in <1% of tested isolates (12/3838).
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Klebsiella pneumoniae
Of CAB, HCAB and HAB caused by K. pneumoniae, 14%, 36%, and 66% were caused by MDR K.
pneumoniae, respectively (p<0.001). Of K. pneumoniae causing CAB, 16% (146/902), 16% (143/894),
23% (198/876), and 9% (94/999) were non-susceptible to cefotaxime, ciprofloxacin, trimethoprim-sul-
phamethoxazole and gentamicin, respectively (Table 5). From 2004 to 2010, the proportions of com-
munity-acquired K. pneumoniae bacteraemia being caused by K. pneumoniae non-susceptible to
extended-spectrum cephalosporins rose from 12% (6/50) to 24% (64/263) (p=0.04) (Figure 4). The
proportions of healthcare-associated and hospital-acquired K. pneumoniae bacteraemia being
caused by K. pneumoniae non-susceptible to extended-spectrum cephalosporins were also high
Figure 1. Location of participating hospitals. These were situated in (1) Nong Khai, (2) Udon Thani, (3) Nakhon
Phanom, (4) Chaiyaphum, (5) Mukdahan, (6) Yasothon, (7) Burirum, (8) Sisaket, and (9) Ubon Ratchathani provinces.
DOI: 10.7554/eLife.18082.003
Lim et al. eLife 2016;5:e18082. DOI: 10.7554/eLife.18082 4 of 18
Research article Epidemiology and Global Health
Table 1. Proportions of bacteraemias being caused by multidrug-resistant (MDR) variants of those bacteria.
Pathogens
Community-acquired bacteraemia
(CAB)
Healthcare-associated bacteraemia
(HCAB)
Hospital-acquired bacteraemia
(HAB) p values
MDR Staphylococcus aureus 94/1176 (8%) 73/259 (28%) 222/446 (50%) <0.001
MDR Enterococcus spp 0/176 (0%) 0/49 (0%) 4/117 (3%) 0.02
MDR Escherichia coli 1177/3382 (35%) 288/494 (58%) 252/403 (63%) <0.001
MDR Klebsiella pneumoniae 146/1010 (14%) 71/196 (36%) 301/455 (66%) <0.001
MDR Pseudomonas aeruginosa 13/286 (5%) 10/103 (10%) 45/179 (25%) <0.001
MDR Acinetobacter spp 125/449 (28%) 58/115 (50%) 374/501 (75%) <0.001
NOTE: CAB was defined as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and without a hospital stay in the
30 days prior to admission. HCAB was defined as the isolation of a pathogenic bacterium from blood taken in the first 2 days of admission and with a
hospital stay within 30 days prior to the admission. HAB was defined as the isolation of a pathogenic bacterium from blood taken after the first 2 days
of admission.
DOI: 10.7554/eLife.18082.004
Table 2. Antibiogram of S. aureus causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 1176 patients)
HCAB
(n = 259 patients)
HAB
(n = 446 patients) p values
Aminoglycosides Gentamicin 24/484 (5%) 16/84 (19%) 66/151 (44%) <0.001
Ansamycins Rifampin 2/129 (2%) 1/19 (5%) 0/38 (0%) 0.37
Anti-MRSA cephalosporins Ceftaroline NA NA NA -
Cefamycins Oxacillin * 80/1145 (7%) 67/247 (27%) 210/441 (48%) <0.001
Fluoroquinolones Ciprofloxacin 3/45 (7%) 2/8 (25%) 4/10 (40%) 0.01
Moxifloxacin NA NA NA -
Folate pathway inhibitors Trimethoprim-sulphamethoxazole 99/1139 (9%) 57/251 (23%) 185/438 (42%) <0.001
Fucidanes Fusidic acid 33/618 (5%) 4/170 (2%) 12/291 (4%) 0.26
Glycopeptides Vancomycin † 4/833 (0.5%) 0/190 (0%) 2/357 (1%) 0.86
Teicoplanin 2/66 (3%) 1/17 (6%) 0/17 (0%) 0.72
Telavancin NA NA NA -
Glycylcyclines Tigecycline NA NA NA -
Lincosamides Clindamycin 118/1147 (10%) 77/251 (31%) 202/438 (46%) <0.001
Lipopeptides Daptomycin NA NA NA -
Macrolides Erythromycin 138/1116 (12%) 76/240 (32%) 222/429 (52%) <0.001
Oxazolidinones Linezolid 0/81 (0%) 0/16 (0%) 0/32 (0%) -
Phenicols Chloramphenicol 6/86 (7%) 4/24 (17%) 2/14 (14%) 0.21
Phosphonic acids Fosfomycin 14/361 (4%) 10/66 (15%) 24/141 (17%) <0.001
Streptogramins Quinupristin-dalfopristin NA NA NA -
Tetracyclines Tetracycline NA NA NA -
Doxycycline NA NA NA -
Minocycline NA NA NA -
MDR 94/1176 (8%) 73/259 (28%) 222/446 (50%) <0.001
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR (one or more of these have to apply): (i) an MRSA is always considered MDR by virtue of being an MRSA
(ii) non-susceptible to 1 agent in 3 antimicrobial categories.
* Defined by using a 30 mg cefoxitin disc and an inhibition zone diameter of <21 mm.
† Defined by using a 30 mg vancomycin disc and an inhibition zone diameter of <15 mm.
DOI: 10.7554/eLife.18082.006
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Figure 2. Trends in proportions of Staphylococcus aureus bacteraemia being caused by MRSA in Northeast Thailand. (A) community-acquired, (B)
healthcare-associated and (C) hospital-acquired Staphylococcus aureus bacteraemia.
DOI: 10.7554/eLife.18082.005
Table 3. Antibiogram of Enterococcus spp. causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 176 patients)
HCAB
(n = 49 patients)
HAB
(n = 117 patients) p values
Aminoglycosides Gentamicin
(high level)
35/153 (23%) 24/45 (53%) 63/101 (62%) <0.001
Streptomycin Streptomycin
(high level)
NA NA NA -
Carbapenems* Imipenem NA NA NA -
Meropenem 1/1 (100%) NA 3/5 (60%) >0.99
Doripenem NA NA NA -
Fluoroquinolones Ciprofloxacin 37/44 (84%) 9/10 (90%) 31/37 (84%) >0.99
Levofloxacin 5/18 (28%) 1/6 (17%) 11/15 (73%) 0.01
Moxifloxacin NA NA NA -
Glycopeptides Vancomycin 9/176 (5%) 0/49 (0%) 6/113 (5%) 0.27
Teicoplanin 0/11 (0%) 0/4 (0%) 0/10 (0%) -
Glycylcyclines Tigecycline NA NA NA -
Lipopeptides Daptomycin NA NA NA -
Oxazolidinones Linezolid 0/8 (0%) 0/2 (0%) 0/4 (0%) -
Penicillins Ampicillin 20/134 (15%) 6/37 (16%) 34/81 (42%) <0.001
Streptogramins* Quinupristin-dalfopristin NA NA NA -
Tetracycline Doxycycline NA NA NA -
Minocycline NA NA NA -
MDR 0/176 (0%) 0/49 (0%) 4/117 (3%) 0.02
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR: non-susceptible to 1 agent in 3 antimicrobial categories.
*Intrinsic resistance in E. faecium against carbapenems and in E. faecalis against streptogramins. When a species has intrinsic resistance to an antimicro-
bial category, that category is removed prior to applying the criteria for the MDR definition and is not counted when calculating the number of catego-
ries to which the bacterial isolate is non-susceptible.
DOI: 10.7554/eLife.18082.008
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(40% [71/177] and 71% [304/431], respectively), but a significant trend over time was not observed
(p=0.16 and p=0.35, respectively). Carbapenem non-susceptible K. pneumoniae was found in <1%
of tested isolates (11/1555).
Pseudomonas aeruginosa
Of CAB, HCAB and HAB caused by P. aeruginosa, 5%, 10%, and 25% were caused by MDR P. aeru-
ginosa, respectively (p<0.001). Of P. aeruginosa causing HAB, 38% (68/179), 27% (48/177), 23% (39/
169) and 26% (42/164) were non-susceptible to commonly-used antimicrobials for HAI such as cefta-
zidime, amikacin, ciprofloxacin and carbapenems, respectively (Table 6). We did not observe a trend
in the proportions of P. aeruginosa being caused by P. aeruginosa that were non-susceptible to any
specific antibiotic group (Figure 5).
Table 4. Antibiogram of E. coli causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 3382
patients)
HCAB
(n = 494
patients)
HAB
(n = 403
patients)
p
values
Aminoglycosides Gentamicin 559/3346 (17%) 166/484 (34%) 178/398 (45%) <0.001
Tobramycin NA NA NA -
Amikacin 72/2685 (3%) 26/397 (7%) 32/326 (10%) <0.001
Netilmicin 68/1394 (5%) 25/259 (10%) 42/254 (17%) <0.001
Anti-MRSA cephalosporins Ceftaroline NA NA NA -
Antipseudomonal penicillins + b lactamase
inhibitors
Ticarcillin-clauvanic acid NA NA NA -
Piperacillin-tazobactam 23/511 (5%) 10/103 (10%) 15/89 (17%) <0.001
Carbapenems Ertapenem 4/1325 (<1%) 1/235 (<1%) 4/205 (2%) 0.02
Imipenem 3/2449 (<1%) 0/386 (0%) 3/344 (1%) 0.04
Meropenem 0/1988 (0%) 1/314 (<1%) 1/244 (<1%) 0.05
Non-extended spectrum cephalosporins Cefazolin 468/1095 (43%) 115/174 (66%) 80/102 (78%) <0.001
Cefuroxime 219/1438 (15%) 96/226 (42%) 102/202 (50%) <0.001
Extended-spectrum cephalosporins Cefotaxime 501/3076 (16%) 199/455 (44%) 185/361 (51%) <0.001
Ceftazidime 392/3020 (13%) 165/446 (37%) 164/351 (47%) <0.001
Cefepime 30/293 (10%) 12/42 (29%) 18/53 (34%) <0.001
Cephamycins Cefoxitin 36/1200 (3%) 16/215 (7%) 16/195 (8%) <0.001
Cefotetan NA NA NA -
Fluoroquinolones Ciprofloxacin 728/3000 (24%) 221/452 (49%) 171/384 (45%) <0.001
Folate pathway inhibitors Trimethoprim-
sulphamethoxazole
1738/3007 (58%) 294/442 (67%) 225/350 (64%) <0.001
Glycylcyclines Tigecycline 0/7 (0%) NA 0/1 (0%) -
Monobactams Aztreonam NA NA NA -
Penicillins Ampicillin 2246/2843 (79%) 371/420 (88%) 301/342 (88%) <0.001
Penicillins + b lactamase inhibitors Amoxicillin-clavulanic acid 790/3074 (26%) 191/463 (41%) 158/373 (42%) <0.001
Ampicillin-sulbactam 83/296 (28%) 18/48 (38%) 12/25 (48%) 0.06
Phenicols Chloramphenicol 14/63 (22%) 1/4 (25%) 3/5 (60%) 0.14
Phosphonic acids Fosfomycin NA NA NA -
Polymyxins Colistin* 2/34 (6%) 0/6 (0%) 1/6 (17%) 0.61
MDR 1177/3382 (35%) 288/494 (58%) 252/403 (63%) <0.001
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR: non-susceptible to 1 agent in 3 antimicrobial categories.
*Defined by using an inhibition zone of <11 mm.
DOI: 10.7554/eLife.18082.009
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Acinetobacter species
Of CAB, HCAB and HAB caused by Acinetobacter spp., 28%, 50%, and 75% were caused by MDR
Acinetobacter spp., respectively (p<0.001). Of Acinetobacter spp. causing HAB, 75% (377/500), 63%
(310/495), 67% (322/481) and 64% (315/490) were non-susceptible to ceftazidime, amikacin, cipro-
floxacin and carbapenems, respectively (Table 7). There was borderline evidence that the proportion
of hospital-acquired Acinetobacter spp. bacteraemia being caused by Acinetobacter spp. non-sus-
ceptible to carbapenem rose from 49% (19/39) in 2004 to 65% (70/108) in 2010 (p=0.10) (Figure 6).
Non-susceptibility to colistin was observed in 3% of tested isolates (2/63).
Mortality attributable to MDR
The 30-day mortality in patients with CAB, HCAB and HAB caused by MDR bacteria was 35% (549/
1555), 49% (247/500), and 53% (640/1198), compared with 32% (1595/4924), 37% (264/716), and
42% (383/903) in CAB, HCAB, and HAB caused by non-MDR bacteria, respectively (Figure 7). In the
final multivariable logistic regression model, gender, age group, year of admission and time to bac-
teraemia (for HAB) were included (Supplementary file 2).
If excess mortality in patients infected with MDR bacteria after adjusting for confounding factors
in the final multivariable model is assumed to be caused by MDR, the mortality attributable to MDR
was 7% (95%CI 4% to 10%, p<0.001) in CAB, 15% (95%CI 5% to 24%, p<0.001) in HCAB and 15%
Figure 3. Trends in proportions of Escherichia coli bacteraemia being caused by E. coli non-susceptible to extended-spectrum cephalosporins in
Northeast Thailand. (A) community-acquired, (B) healthcare-associated and (C) hospital-acquired E. coli bacteraemia.
DOI: 10.7554/eLife.18082.007
Figure 4. Trends in proportions of Klebsiella pneumoniae bacteraemia being caused by K. pneumoniae non-susceptible to extended-spectrum
cephalosporins in Northeast Thailand. (A) community-acquired, (B) healthcare-associated and (C) hospital-acquired K. pneumoniae bacteraemia.
DOI: 10.7554/eLife.18082.010
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(95%CI 2% to 27%, p<0.001) in HAB (Figure 7). Heterogeneity between different organisms was
clearly observed in HAB (p<0.001), and borderline evidence of heterogeneity was observed in HCAB
(p=0.09). The heterogeneity observed in HCAB and HAB was largely caused by MDR Acinetobacter
spp. (Figure 7B and C). Mortality attributed to MDR was highest for hospital-acquired MDR Acineto-
bacter bacteraemia (41%).
Using our estimated mortality attributed to MDR bacteraemia (Figure 7C) and national statistics
of HAI caused by MDR bacteria, we further estimated that 19,122 of 45,209 (43%) deaths in patients
with HAI due to MDR bacteria in Thailand in 2010 represented excess mortality caused by MDR
(Table 8). All parameters used to estimate the number of excess deaths in Thailand are shown in
Supplementary file 2.
Table 5. Antibiogram of K. pneumoniae causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 1010
patients)
HCAB
(n = 196
patients)
HAB
(n = 455
patients)
p
values
Aminoglycosides Gentamicin 94/999 (9%) 53/193 (27%) 265/444 (60%) <0.001
Tobramycin NA NA NA -
Amikacin 17/815 (2%) 12/157 (8%) 109/398 (27%) <0.001
Netilmicin 20/450 (4%) 23/112 (21%) 124/320 (39%) <0.001
Anti-MRSA cephalosporins Ceftaroline NA NA NA -
Antipseudomonal penicillins + b lactamase
inhibitors
Ticarcillin-clauvanic acid NA NA NA -
Piperacillin-tazobactam 24/166 (14%) 14/32 (44%) 73/121 (60%) <0.001
Carbapenems Ertapenem 2/432 (0%) 1/100 (1%) 5/264 (2%) 0.17
Imipenem 1/778 (0%) 1/164 (1%) 2/408 (0%) 0.24
Meropenem 0/583 (0%) 1/113 (1%) 2/317 (1%) 0.10
Non-extended spectrum cephalosporins Cefazolin 76/319 (24%) 30/60 (50%) 101/127 (80%) <0.001
Cefuroxime 81/478 (17%) 35/98 (36%) 161/231 (70%) <0.001
Extended-spectrum cephalosporins Cefotaxime 146/902 (16%) 71/173 (41%) 298/424 (70%) <0.001
Ceftazidime 124/927 (13%) 63/176 (36%) 295/430 (69%) <0.001
Cefepime 5/100 (5%) 8/22 (36%) 25/51 (49%) <0.001
Cephamycins Cefoxitin 15/396 (4%) 10/95 (11%) 14/230 (6%) 0.03
Cefotetan NA NA NA -
Fluoroquinolones Ciprofloxacin 143/894 (16%) 66/176 (38%) 187/430 (43%) <0.001
Folate pathway inhibitors Trimethoprim-
sulphamethoxazole
198/876 (23%) 69/171 (40%) 219/407 (54%) <0.001
Glycylcyclines Tigecycline NA NA NA -
Monobactams Aztreonam NA NA NA -
Penicillins + b lactamase inhibitors Amoxicillin-clavulanic acid 131/945 (14%) 68/183 (37%) 291/443 (66%) <0.001
Ampicillin-sulbactam 20/105 (19%) 9/17 (53%) 23/38 (61%) <0.001
Phenicols Chloramphenicol 4/19 (21%) 0/2 (0%) 0/3 (0%) >0.99
Phosphonic acids Fosfomycin NA NA NA -
Polymyxins Colistin * 0/6 (0%) 0/2 (0%) 0/5 (0%) -
MDR 146/1010 (14%) 71/196 (36%) 301/455 (66%) <0.001
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR: non-susceptible to 1 agent in 3 antimicrobial categories.
* Defined by using an inhibition zone of <11 mm.
DOI: 10.7554/eLife.18082.011
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Discussion
This study presents detailed antimicrobial susceptibility data on common pathogenic bacteria, the
association of MDR with infection acquisition (community-acquired, healthcare-associated and hospi-
tal-acquired), and excess mortality from MDR in a developing country. Our estimate of excess deaths
caused by MDR in HAI patients in Thailand (19,122 deaths per year in a country of about 66 million
population in 2010) is large compared to those estimated in USA (23,000 death per year in a country
Table 6. Antibiogram of P. aeruginosa causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 286 patients)
HCAB
(n = 103 patients)
HAB
(n = 179 patients) p values
Aminoglycosides Gentamicin 29/235 (12%) 13/88 (15%) 60/140 (43%) <0.001
Tobramycin NA NA NA -
Amikacin 27/284 (10%) 13/100 (13%) 48/177 (27%) <0.001
Netilmicin 8/155 (5%) 5/67 (7%) 34/120 (28%) <0.001
Antipseudomonal carbapenems Imipenem 14/238 (6%) 6/86 (7%) 37/154 (24%) <0.001
Meropenem 9/163 (6%) 8/73 (11%) 24/125 (19%) 0.001
Doripenem 2/17 (12%) 0/3 (0%) 2/2 (100%) 0.04
Antipseudomonal cephalosporins Ceftazidime 29/280 (10%) 16/103 (16%) 68/179 (38%) <0.001
Cefepime 2/36 (6%) 2/18 (11%) 10/28 (36%) 0.01
Antipseudomonal fluoroquinolones Ciprofloxacin 24/275 (9%) 12/101 (12%) 39/169 (23%) <0.001
Levofloxacin 0/1 (0%) 1/1 (100%) 1/1 (100%) >0.99
Antipseudomonal penicillins + b lactamase inhibitors Ticarcillin-clauvanic acid NA NA NA -
Piperacillin-tazobactam 8/85 (9%) 6/38 (16%) 8/46 (17%) 0.37
Monobactams Aztreonam NA NA NA -
Phosphonic acids Fosfomycin 1/1 (100%) NA NA -
Polymyxins Colistin 0/7 (0%) 0/3 (0%) 1/7 (14%) >0.99
Polymyxin B NA NA NA -
MDR 13/286 (5%) 10/103 (10%) 45/179 (25%) <0.001
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR: non-susceptible to 1 agent in 3 antimicrobial categories.
DOI: 10.7554/eLife.18082.013
Figure 5. Trends in proportions of Pseudomonas aeruginosa bacteraemia being caused by P. aeruginosa non-susceptible to carbapenem in Northeast
Thailand. (A) community-acquired, (B) healthcare-associated and (C) hospital-acquired Pseudomonas aeruginosa bacteraemia.
DOI: 10.7554/eLife.18082.012
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Table 7. Antibiogram of Acinetobacter spp. causing bacteraemia in Northeast Thailand.
Antibiotic category Antibiotic agents
CAB
(n = 449
patients)
HCAB
(n = 115
patients)
HAB
(n = 501
patients)
p
values
Aminoglycosides Gentamicin 112/390 (29%) 45/105 (43%) 310/455 (68%) <0.001
Tobramycin NA NA NA -
Amikacin 123/442 (28%) 45/112 (40%) 310/495 (63%) <0.001
Netilmicin 44/203 (22%) 24/64 (38%) 224/381 (59%) <0.001
Antipseudomonal carbapenems Imipenem 87/397 (22%) 37/102 (36%) 293/459 (64%) <0.001
Meropenem 65/284 (23%) 32/81 (40%) 229/348 (66%) <0.001
Doripenem 16/45 (36%) 9/10 (90%) 6/7 (86%) 0.001
Antipseudomonal fluoroquinolones Ciprofloxacin 84/413 (20%) 53/106 (50%) 322/481 (67%) <0.001
Levofloxacin 2/5 (40%) 2/2 (100%) 8/9 (89%) 0.11
Antipseudomonal penicillins + b lactamase
inhibitors
Ticarcillin- clauvanic acid NA NA NA -
Piperacillin-tazobactam 22/98 (22%) 13/28 (46%) 74/106 (70%) <0.001
Extended-spectrum cephalosporins Cefotaxime 242/291 (83%) 89/94 (95%) 407/420 (97%) <0.001
Ceftazidime 133/448 (30%) 61/114 (54%) 377/500 (75%) <0.001
Cefepime 18/53 (34%) 10/22 (45%) 95/133 (71%) <0.001
Folate pathway inhibitor Trimethopri-
sulphamethoxazole
119/356 (33%) 55/99 (56%) 333/435 (77%) <0.001
Penicillins + b lactamase inhibitors Ampicillin-sulbactam 43/134 (32%) 16/29 (55%) 79/115 (69%) <0.001
Polymyxins Colistin * 2/16 (13%) 0/14 (0%) 0/33 (0%) 0.11
Polymyxin B NA NA NA -
Tetracyclines Tetracycline NA NA NA -
Doxycycline NA NA NA -
Minocycline NA NA NA -
MDR 125/449 (28%) 58/115 (50%) 374/501 (75%) <0.001
NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%).
CAB = Community-acquired bacteraemia, HCAB = Healthcare-associated bacteraemia, HAB = Hospital-acquired bacteraemia, and NA = Not available.
The first isolate of each patient was used. MDR: non-susceptible to 1 agent in 3 antimicrobial categories.
* Defined by using an inhibition zone of <11 mm.
DOI: 10.7554/eLife.18082.015
Figure 6. Trends in proportions of Acinetobacter spp bacteraemia being caused by Acinetobacter spp non-susceptible to carbapenem in Northeast
Thailand. (A) community-acquired, (B) healthcare-associated and (C) hospital-acquired Acinetobacter spp bacteraemia.
DOI: 10.7554/eLife.18082.014
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Figure 7. Forest plot of mortality in patients with MDR bacteraemia compared with non-MDR bacteraemia in Northeast Thailand. (A) Community-
acquired bacteraemia. (B) Healthcare-associated bacteraemia. (C) Hospital-acquired bacteraemia.
DOI: 10.7554/eLife.18082.016
The following source data is available for figure 7:
Source data 1. Mortality in patients with MDR and non-MDR bacteraemia in Northeast Thailand.
DOI: 10.7554/eLife.18082.017
Table 8. Estimates of mortality attributable to multidrug-resistance (MDR) in hospital-acquired infection (HAI) in Thailand.
Pathogens
No of
patients*
Estimated
mortality (%)†
Estimated mortality if the infections were caused by
non-MDR organisms (%)†, ‡
Estimated excess mortality caused
by MDR (%)†, ‡
MDR Staphylococcus
aureus
18,725 8262 (44%) 5463 (29%) 2799 (15%)
MDR Escherichia coli 11,116 2163 (19%) 1566 (14%) 597 (5%)
MDR Klebsiella
pneumoniae
15,239 5267 (35%) 4979 (33%) 288 (2%)
MDR Pseudomonas
aeruginosa
6118 3966 (65%) 3696 (60%) 270 (4%)
MDR Acinetobacter
spp
36,553 25,551 (70%) 10,383 (28%) 15,168 (41%)
Total 87,751 45,209 (52%) 26,087 (30%) 19,122 (22%)
*Cumulative incidence of antimicrobial resistant HAI in Thailand 2010 estimated by Pumart et al. (2012).
†All parameters used to estimate the mortality and excess mortality are shown in Supplementary file 2.
‡Excess mortality caused by MDR (mortality attributable to MDR) was defined as the difference in mortality of patients with MDR infection and their mor-
tality if they were infected with non-MDR infections.
DOI: 10.7554/eLife.18082.018
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of 316 million population in 2013) (Center for Disease Controls and Prevention and U.S. Depart-
ment of Health and Human Services, 2013) and the European Union (25,000 deaths per year in EU
of about 500 million population in 2007) (European Centre for Disease Prevention and Control
and European Medicines Agency, 2009). Our study highlights the need for public health officials
and international health organizations to improve systems to track and reduce the burden of AMR in
LMICs. Our estimated mortality for those with MDR HAI (45,209, Table 2) is higher than those previ-
ously published by Pumart et al. (38,481) (Pumart et al., 2012), probably because we used 30-day
mortality rather than in-hospital mortality.
Acinetobacter spp. is increasingly recognized as an important cause of HAI, (Munoz-Price and
Weinstein, 2008; Peleg and Hooper, 2010) and our study confirms the importance of this species
as a leading cause of hospital-acquired MDR infection in a developing tropical country
(Hongsuwan et al., 2014; Nhu et al., 2014). The high mortality observed in MDR Acinetobacter
spp. bacteraemia is because treatment options are limited and those available are associated with
toxicity (Fishbain and Peleg, 2010). The high proportions of S. aureus, E. coli and K. pneumoniae
bactaeremia being caused by MRSA and E. coli and K. pneumoniae non-susceptible to extended-
spectrum cephalosporins, respectively, are consistent with previous reports from other tropical coun-
tries (Moreno et al., 2006; Cuellar et al., 2008; Rosenthal et al., 2003). The rising proportions of
community-acquired E. coli and K. pneumoniae bacteraemia being caused by E. coli and K. pneumo-
niae non-susceptible to extended-spectrum cephalosporins, and the rising proportion of hospital-
acquired Acinetobacter bacteraemia being causing Acinetobacter non-susceptible to carbapenem
suggest that the burden of AMR in Thailand is deteriorating over time.
A limitation of this study is that more complete clinical data were not available. Mortality attribut-
able to MDR could be overestimated if MDR infection was associated with more severely ill patients
in ICUs. However, our estimated attributable mortality is comparable to the previous reports. For
example, our estimated mortality attributable to MDR Acinetobacter bacteraemia (40.6%) is compa-
rable to the mortality attributable to imipenem resistant Acinetobacter bacteraemia reported by
Kwon et al. in Korea (41.1%), which was adjusted by severity of illness (Kwon et al., 2007;
Falagas and Rafailidis, 2007). In addition, data on hospitalization in other hospitals not participating
in the study (for example, a smaller community hospital or a private hospital in the province) were
not available, which could have resulted in a misclassification of CAB, HCAB and HAB in some cases.
We also note that data on attributable mortality from different countries is difficult to compare
because of the differing study designs. For example, our mortality outcome is the overall 30-day
mortality, including both directly and indirectly contributed to MDR, while an EU study only consid-
ered directly attributable deaths (European Centre for Disease Prevention and Control and Euro-
pean Medicines Agency, 2009). The p values for trends were generated by the stratification
method; therefore, the analysis was not biased towards the increasing availability of the hospital
data over the study period. Nonetheless, the trends could be affected by an increasing use of blood
culture, changes in antimicrobial agents tested for susceptibility, and greater standardization of lab-
oratory methodologies over time (Opartkiattikul and Bejrachandra, 2002). It is likely that
the burdens of MDR similar to that observed in our study are present in many secondary and tertiary
hospitals in tropical LMICs, particularly where extended-spectrum cephalosporins and carbapenem
are widely used. Nonetheless, resources for diagnostics, methodologies used in the laboratories,
and study designs need to be carefully considered when performing a comparison between different
settings.
Despite the increasing global focus on AMR in LMICs, considerable gaps remain in our under-
standing of the scale of the problem. We have demonstrated that the integration of information
from readily available routinely collected databases can provide valuable information on the trends
and mortality attributable to AMR in Thailand. The methodology used in our study could be applied
to explore the burden of AMR in other LMICs where microbiological facilities and hospital admission
database are available.
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Materials and methods
Study population
From 2004 to 2010, Thailand was classified as a lower-middle income country with an average
income of $4782 per person per year in 2010 (WorldBank, 2015). Northeast Thailand consists of 20
provinces covering 170,226 km and had an estimated population of 21.4 million in 2010. A large
proportion of the population in this area lives in rural settings, with most adults engaging in agricul-
ture with an emphasis on rice farming. Healthcare in Thailand is mainly provided by government-
owned hospitals. Each province has a provincial hospital, which provides services and care to individ-
uals within its catchment area. Additionally, provincial hospitals act as referral hospitals for smaller
community hospitals for severely ill patients. All provincial hospitals receive comparable resources,
which are proportional to the respective populations of the provinces. Provincial hospitals, unlike
smaller community hospitals, are equipped with a microbiology laboratory capable of performing
bacterial culture using standard methodologies for bacterial identification and susceptibility testing
provided by the Bureau of Laboratory Quality and Standards, Ministry of Public Health (MoPH), Thai-
land (Opartkiattikul and Bejrachandra, 2002). During the study period, antimicrobial susceptibility
was determined in all study hospitals using the disc diffusion method according to Clinical and Labo-
ratory Standards Institute (CLSI) (National Committee for Clinical Laboratory Standards, 2004).
Study design
We conducted a retrospective, multicentre surveillance study of all provincial hospitals in Northeast
Thailand. From the hospitals that agreed to participate, data were collected from microbiology and
hospital databases between January 2004 and December 2010. Hospital number (HN) and admission
number (AN) were used as a record linkage between the two databases and to identify individuals
who had repeat admissions. The death registry for Northeast Thailand was obtained from the Minis-
try of Interior (MoI), Thailand, and used to identify patients who were discharged from hospital but
died at home shortly after, which is a common practice in Thailand (Kanoksil et al., 2013;
Hongsuwan et al., 2014). Ethical permission for this study was obtained from the Ethical and Scien-
tific Review Committees of the Faculty of Tropical Medicine, Mahidol University, and of the MoPH,
Thailand. Written consent was given by the directors of the hospitals to use their routine hospital
database for research. Consent was not sought from the patients as this was a retrospective study,
and the Ethical and Scientific Review Committees approved the process.
Data collection
The microbiology laboratory data collected included hospital number (HN), admission number (AN),
specimen type, specimen date, culture result, and antibiotic susceptibility profile (antibiogram). We
consulted with study sites when the results of antimicrobial susceptibility testing were unclear. Hos-
pital admission data were collected from the routine in-patient discharge report, which is regularly
completed by attending physicians and reported to the MoPH, Thailand, as part of the national mor-
bidity and mortality reporting system. The data collected included HN, AN, national identification
13-digit number, admission date, and discharge date. Date of death was also extracted from this
record. Data collected from the national death registry obtained from the MoI included the national
identification 13-digit number and the date of death.
Definitions
Bacteraemia was classified as CAB, HAB and HCAB as described previously (Kanoksil et al., 2013;
Hongsuwan et al., 2014). Polymicrobial infection was defined in patients who had more than one
species of pathogenic organisms isolated from the blood during the same episode, and was
excluded from the analysis. Information on the incidence of CAB, HCAB and HAB from all patho-
genic organisms has been published previously (Kanoksil et al., 2013; Hongsuwan et al., 2014).
The 30-day mortality of CAB and HCAB was defined as death within 30 days of the admission
date. The 30-day mortality of HAB was determined on the basis of a record of death within 30 days
of the positive blood culture taken as recorded in the routine hospital database or by a record of
death in the national death registry. In the event that a patient had more than one episode of bac-
teraemia, only the first episode was included in the study.
Lim et al. eLife 2016;5:e18082. DOI: 10.7554/eLife.18082 14 of 18
Research article Epidemiology and Global Health
The standard definition of MDR proposed by ECDC/CDC was used (Magiorakos et al., 2012). In
brief, MDR was defined as non-susceptibility to at least one agent in three or more antimicrobial cat-
egories. Additionally, methicillin-resistant Staphylococcus aureus (MRSA) were automatically
described as MDR (Magiorakos et al., 2012).
Statistical analysis
Pearson’s chi-squared test and Fisher’s Exact test were used to compare categorical variables. A
non-parametric test for trends was used to assess changes in prevalence of antimicrobial resistance
over time stratified by hospital (using the npt_s command in STATA).
Mortality of patients with a first episode of HAB, HCAB and HAB caused by S. aureus, Enterococ-
cus spp., E. coli, K. pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. were evaluated
in relation to MDR. We selected these organisms based on guidelines for MDR proposed by ECDC/
CDC, (Magiorakos et al., 2012) and the fact that E. coli and K. pneumoniae were the most common
causes of bacteraemia caused by Enterobacteriaceae in our setting (Kanoksil et al., 2013;
Hongsuwan et al., 2014). Isolates tested for less than three antimicrobial categories were excluded
from the analysis because they were not applicable to ECDC/CDC standard definitions of MDR. To
examine the association between MDR and mortality, we performed a multivariable logistic regres-
sion analysis adjusting for a priori selected baseline confounders. To take account of the fact that
patients with CAB, HCAB, and HAB were different populations with different definitions of 30-day
mortality, we applied models to each group (CAB, HCAB and HAB) separately. Multivariable logistic
regression models were developed using a purposeful selection method (Bursac et al., 2008).
Potential confounding variables evaluated included age, gender and admission year. In the model
for HAB, time to bacteraemia was also evaluated as a potential confounder because there was evi-
dence suggesting that time to HAI was associated with mortality from HAI (Moine et al., 2002;
Nguile-Makao et al., 2010). Time to bacteremia was defined as the duration between hospital
admission and the date positive blood culture was taken. All models were stratified by hospital.
The mortality attributable to MDR was calculated using adjusted odds ratios (aORs) estimated by
the final multivariable logistic regression models. If X was the observed mortality in patients with
MDR infection, the estimated odds of mortality if they were infected with non-MDR organisms (O)
would be (1/aOR)*(X/(1-X)). Assuming that excess mortality was due to MDR, then the mortality
attributable to MDR would be the absolute difference between mortality in patients with MDR infec-
tion (X) and the predicted mortality if they were infected with non-MDR organisms (O/(1+O)), which
would be X – (O/(1+O)) (Benichou, 2001; Greenland and Robins, 1988). Heterogeneity between
different organisms within each group of patients (CAB, HCAB, and HAB) was assessed using the
chi-squared test, and the percentage of variation due to heterogeneity (I-square) was calculated.
The number of deaths attributable to MDR in Thailand was determined using the methodology
described previously (European Centre for Disease Prevention and Control and European Medi-
cines Agency, 2009). Data used included our estimated mortality attributable to MDR bacteraemia
and cumulative incidence of HAI bacteraemia, lower respiratory track infection (LRTI), urinary tract
infection (UTI), skin and soft tissue infection (SSTI), and other sites of infection caused by MDR S.
aureus, E. coli, K. pneumoniae, P. aeruginosa, and Acinetobacter spp. in Thailand in 2010, which
have been described previously (Pumart et al., 2012). Death attributable to MDR Enterococcus spp.
was not included as the cumulative incidence of MDR Enterococcus infection in Thailand was not
available (Pumart et al., 2012). Attributable mortality by site of infection (LRTI, UTI, SSTI and other
site) was estimated by applying correction factors corresponding to the relative mortality from infec-
tions of those sites compared to bacteraemia (Martone et al., 1998). All analyses were performed
using STATA version 14.0 (StataCorp LP, College station, Texas, USA).
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